Biosimilar Antibodies
| Cat.No. | Product Name | Information | Isotype |
|---|---|---|---|
| A2994 | Favezelimab (Anti-LAG3 / CD223) | Favezelimab (Anti-LAG3 / CD223) is a humanised monoclonal antibody that targets LAG-3. It has the potential for colorectal cancer (CRC) research. MW: 145.98 KD. | Human IgG4SP |
| A2739 | Anti-158P1D7 | Anti-158P1D7 is a monoclonal Anti-158P1D7 antibody used in the production of antibody drug conjugates (adc) that bind to 158P1D7 proteins. MW: 146.0 KD. | Human IgG2SA |
| A2995 | Fianlimab (Anti-LAG3 / CD223) | Fianlimab (Anti-LAG3 / CD223) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells. It has anti-tumour activity and can be used in treatment of advanced melanoma. MW :145.72 KD. | Human IgG4SP |
| A2740 | Anti-Dysadherin | Anti-Dysadherin is a monoclonal antibody against dysadherin with anti-metastasis activity. MW: 147.56 KD. | Human IgG1 |
| A2996 | Ieramilimab (Anti-LAG3 / CD223) | Ieramilimab (Anti-LAG3 / CD223) is a humanized IgG4 monoclonal antibody that targets LAG-3. It has antitumor activity and can be used in treatment of advanced malignancies MW :146.78 KD. | Human IgG4SP |
| A2741 | Anti-TMEFF1 / Tomoregulin-1 | Anti-TMEFF1 / Tomoregulin-1 is a monoclonal antibody against TMEFF1 (a transmembrane protein with EGF-like and two Follistatin-like domains, Tomoregulin 1), a type I transmembrane glycoprotein. MW: 146.08 KD. | Human IgG1 |
| A2997 | Miptenalimab (Anti-LAG3 / CD223) | Miptenalimab (Anti-LAG3 / CD223) is an anti-human LAG-3 antibody. It leads to increased immune cell responses. MW: 146.12 KD. | Human IgG4SP |
| A2742 | Anti-c-RET | Anti-c-RET is a monoclonal antibody against the receptor tyrosine kinase Ret (c-Ret) expressed in cells of neuroblastoma and substantia nigra, a responsive locus of Parkinson's disease. MW: 146.74 KD. | Human IgG1 |
| A2998 | Opucolimab (Anti-B7-H1 / PD-L1 / CD274) | Opucolimab (Anti-B7-H1 / PD-L1 / CD274) is a recombinant human monoclonal antibody targeting PD-L1. It can be used for the research of advanced solid tumours. MW: 144.68 KD. | Human IgG1 |
| A2743 | Cantuzumab (Anti-MUC1) | Cantuzumab (Anti-MUC1) is a humanized monoclonal antibody that targets against cell surface-associated mucin 1 (MUC1) expressed in most pancreatic cancers. MW: 147.02 kD. | Human IgG1 |
| A2744 | Abituzumab (Anti-Integrin aV / ITGAV / CD51) | Abituzumab (Anti-Integrin aV / ITGAV / CD51) is a humanized monoclonal antibody directed against the human alpha v integrin subunit with potential antiangiogenic and antineoplastic activities.MW: 144.78 kD. | Human IgG2SA |
| A3000 | Orilanolimab (Anti-FcRn (FCGRT & B2M)) | Orilanolimab (Anti-FcRn (FCGRT & B2M)) is a humanized monoclonal antibody targeting FcRn. It disrupts the interaction of FcRn and IgG for the treatment autoimmune diseases. MW: 144.28 KD. | Human IgG4SP |
| A2745 | Anti-Integrin a11 / ITAG11 | Anti-Integrin a11 / ITAG11 is a monoclonal antibody against Integrin alpha 11 (ITGA11), a transmembrane glycoprotein expressed in adult cardiac and uterine smooth muscle and developing myocytes. MW: 145.7 KD. | Human IgG2SA |
| A3001 | Anti-AXL / UFO (ORY012) | Anti-AXL / UFO (ORY012) is a polyclonal antibody that targets receptor tyrosine kinase AXL (UFO). It can be used in research of glioblastoma multiforme (GBM) and pancreatic cancers. MW: 146.28 KD. | Human IgG1 |
| A2746 | Cevostamab (Anti- FcRH5 / IRTA2 / CD307e) | Cevostamab (Anti- FcRH5 / IRTA2 / CD307e) is a humanised IgG1-based bispecific antibody that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. MW: 145.24 kD. | Human IgG1 |
| A3002 | Anti-Mesothelin (BMS-986148) | Anti-Mesothelin (BMS-986148) is a fully human IgG1 monoclonal antibody targeting mesothelin. It is used to synthesize antibody-drug conjugate (ADC). It has potential multimodal therapeutic strategies in patients with advanced solid tumours. MW :150 KD. | Human IgG1 |
| A2747 | Cusatuzumab (Anti-TNFSF7 / CD27L / CD70) | Cusatuzumab (Anti-TNFSF7 / CD27L / CD70) is a defucosylated, humanized IgG1 monoclonal antibody directed against the extracellular domain of the human CD70 molecule with potential antineoplastic activity. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML). MW: 144.36 kD. | Human IgG1 |
| A2748 | Anti-SCFR / c-Kit / CD117 (CDX-0158) | Anti-SCFR / c-Kit / CD117 (CDX-0158) is a humanized immunoglobulin (Ig) G1 monoclonal antibody against the stem cell factor receptor c-Kit (SCFR; KIT; CD117), with potential antineoplastic and anti-allergic activities. CDX‐0159 inhibits SCF‐dependent KIT and mast cell activation. MW: 145.1 kD. | Human IgG1 |
| A3004 | Otelixizumab (Anti-CD3) | Otelixizumab (Anti-CD3) is a human monoclonal antibody targeting CD3. It can be used for the research of type 1 diabetes. MW: 145.14 KD. | Human IgG1 |
| A2749 | Anti-DSG3 | Anti-DSG3 is an anti-desmoglein 3 (Dsg3) monoclonal antibody that depletes desmosomes of Dsg3 and has the potential to be used in research on Pemphigus vulgaris (PV). MW: 146.54 KD. | Human IgG1 |
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.